Core Insights - Knight Therapeutics Inc. reported record-high revenues, adjusted EBITDA, and cash flow from operations since its inception, with 2026 revenue guidance of CAD 490 million to CAD 510 million and adjusted EBITDA of approximately 15% [1][51]. Financial Results - Revenues for 2025 were CAD 450,088, an increase of CAD 78,784 or 21% compared to the previous year, driven by incremental revenues from the Paladin and Sumitomo transactions and growth in key promoted products [6][14]. - Gross margin was 44% of revenues, down from 47% in the prior year, primarily due to hyperinflation impacts and fair value adjustments on inventory from the Paladin transaction [6][21]. - Operating loss was CAD 2,350 compared to an operating income of CAD 7,397 in the prior year, while net loss was CAD 5,374 compared to a net income of CAD 4,332 [6][26]. - Cash inflow from operations was CAD 68,957, a 90% increase over the prior year [6]. - Adjusted EBITDA was CAD 73,056, a 26% increase over the previous year, with adjusted EBITDA per share at CAD 0.74, up 28% [6][12]. Corporate Developments - The company launched a Normal Course Issuer Bid (NCIB) to repurchase up to 3,000,000 common shares and purchased 1,130,600 shares at an average price of CAD 5.69 in 2025 [6][9]. - Knight closed a secured syndicated revolving credit facility for USD 100 million and a working capital line of credit agreement with Citibank [6][9]. - The company executed an asset purchase agreement to acquire the Paladin business for CAD 90,002, with additional payments expected based on sales milestones [6][36]. Product Updates - Knight expanded its product portfolio significantly, adding over fifty products, including eight pipeline and early launch stage assets [6][9]. - The company launched multiple innovative products in Canada and Latin America, including Minjuvi and Pemazyre, and submitted several products for regulatory approval [6][41][45]. - Revenues from key promoted products in Oncology/Hematology increased by CAD 14,531 or 20% on a constant currency basis, driven by new product launches [18][19]. Financial Outlook - For fiscal 2026, Knight expects revenues between CAD 490 million to CAD 510 million and adjusted EBITDA to be approximately 15% of revenues, based on various assumptions regarding market conditions and product performance [51][54].

Core Viewpoint - Calfrac Well Services Ltd. reported its financial and operational results for the year ended December 31, 2025, highlighting a stronger financial position despite a decrease in revenue due to lower activity levels in Argentina and North America [1][3]. Financial Performance - Revenue for Q4 2025 was C$292.2 million, a decrease of 23% from Q4 2024, primarily due to lower activity in Argentina, partially offset by higher activity in North America [12]. - Adjusted EBITDA for Q4 2025 was C$43.9 million, an increase of 27% from C$34.5 million in Q4 2024, driven by improved operating results in North America [12]. - Cash flows from operating activities for Q4 2025 were C$98.8 million, up 9% from C$91.0 million in Q4 2024, reflecting better operating results and improved working capital management [12]. - Net income for Q4 2025 was C$14.5 million or C$0.16 per share diluted, compared to a net loss of C$6.4 million or C$0.07 per share diluted in Q4 2024 [12][44]. Operational Highlights - In North America, revenue decreased to C$227.7 million in Q4 2025 from C$289.9 million in Q4 2024, attributed to a lower number of fracturing fleets and reduced oil-directed activity [15]. - The number of fracturing jobs in North America decreased by 10% year-over-year, with a total of 7,185 jobs in Q4 2025 [10]. - In Argentina, revenue for Q4 2025 was C$64.5 million, down 29% from C$91.3 million in Q4 2024, primarily due to a slowdown in industry activity [23]. Capital Expenditures - Capital expenditures for Q4 2025 were C$16.7 million, a decrease of 49% from C$32.9 million in Q4 2024, with a significant portion allocated to expansion capital and infrastructure upgrades in Argentina [30]. Outlook - The outlook for 2026 in North America is positive, with expectations of a moderate increase in oil-directed activity and stable natural gas activity, supported by increased LNG export capacity [13][14]. - In Argentina, the Vaca Muerta shale play is expected to see strong activity levels, with the company anticipating high utilization of its unconventional fracturing fleets [21][22].

Core Insights - Trinseo reported a net loss of $251 million in Q4 2025, significantly impacted by restructuring charges and lower sales volumes across all business segments [1][2][3] - Full-year net sales decreased by 15% to approximately $3.0 billion, with a net loss of $546 million, reflecting ongoing market challenges and restructuring costs [1][2][3] Fourth Quarter 2025 Highlights - Adjusted EBITDA was $26 million, which included $6 million of unfavorable net timing and negative equity income from Americas Styrenics [1][2] - Net sales for Q4 were $663 million, down 19% year-over-year due to lower sales volume and competitive pricing pressure [1][3] - Cash provided by operations was $23 million, leading to a Free Cash Flow of $7 million [1][2] Full-Year 2025 Summary - Adjusted EBITDA for the year was $163 million, $41 million lower than the previous year, influenced by lower sales volumes and margins [1][2] - The company incurred pre-tax restructuring charges of $140 million and $26 million in debt refinancing costs [1][3] - Cash used in operations totaled $102 million, resulting in a Free Cash Flow of negative $153 million [1][2] Business Segment Performance - Americas Styrenics reported an Adjusted EBITDA of negative $7 million, an improvement from the previous year due to higher polystyrene volumes [1][3] - Polymer Solutions net sales decreased by 25% to $246 million, with Adjusted EBITDA of $15 million, reflecting unfavorable mix and lower volumes [1][2] - Latex Binders saw a 19% decline in net sales to $176 million, with Adjusted EBITDA dropping to $9 million due to lower volumes and margins [1][3] - Engineered Materials net sales were $240 million, down 13% year-over-year, while Adjusted EBITDA remained flat at $27 million [1][2] Strategic Focus and Outlook - The company is focused on improving its capital structure and has engaged with financial stakeholders to enhance profitability and cash flow [1][2] - Trinseo continues to invest in technology and innovation in strategic areas such as battery binders and recycled content platforms [1][2]

Financial Data and Key Metrics Changes - In Q4 2025, net revenue reached $128.6 million, a significant increase from $31.2 million in Q4 2024, primarily driven by DefenCath's contribution of $91.2 million and Melinta's contribution of $37.4 million [16][17] - For the full year 2025, total revenue on a pro forma basis was $401.3 million, aligning with previously established guidance [16] - The company reported a net income of $14 million in Q4 2025, impacted by a tax expense of $42.4 million, mostly non-cash [18][19] - Adjusted EBITDA for Q4 was $77.2 million, reflecting modest growth quarter-over-quarter [19][20] - Cash and cash equivalents at the end of Q4 were $148.5 million, supported by strong operating cash flow of nearly $100 million during the quarter [20] Business Line Data and Key Metrics Changes - DefenCath generated $258.8 million in net sales for the full year 2025, with peak sales of just under $260 million achieved [5][16] - The Melinta portfolio contributed $37.4 million in Q4 2025, marking its first full reporting period post-acquisition [16] Market Data and Key Metrics Changes - The company anticipates a revenue concentration for DefenCath to be front-loaded in the first half of 2026, with expected price erosion in the latter half due to the transition to a bundled add-on reimbursement mechanism [6][7] - The estimated market opportunity for REZZAYO is approximately $2.5 billion across its indications, while DefenCath and TPN are estimated between $500 million and $750 million [9] Company Strategy and Development Direction - The company is focused on maintaining patient utilization rates for DefenCath and negotiating pricing structures for 2026 and 2027 [6][7] - The acquisition of Melinta Therapeutics is seen as a strategic move to enhance growth, with a focus on integrating operations and achieving synergies [5][10] - The company is actively pursuing discussions with Medicare Advantage providers and new customers for DefenCath [8] Management's Comments on Operating Environment and Future Outlook - Management views 2025 as a transformational year and expects 2026 to be transitional, setting the stage for long-term sustainable growth [21] - The company remains confident in its financial flexibility and commercial momentum, positioning itself for both organic and inorganic growth opportunities [21] Other Important Information - The company completed its first analyst R&D day, focusing on educating stakeholders about the market opportunity for REZZAYO and its pipeline assets [8][9] - The phase 3 ReSPECT study for REZZAYO is on track for top-line data release in Q2 2026 [11][12] Q&A Session Summary Question: Update on dialysis customer conversations regarding DefenCath pricing - Management indicated that conversations are progressing well, focusing on preserving patient utilization and negotiating pricing structures for 2027 [23] Question: Clinical significance of REZZAYO phase 3 data - Management highlighted the importance of pathogen data and secondary endpoints in guiding commercial utility and marketing strategies [24][25] Question: Developments on TDAPA extension bills - Management noted that timing is uncertain due to legislative complexities and current global events, but they are actively working on the issue [29][30] Question: Inpatient opportunity with DefenCath and Melinta product portfolio - Management discussed the current customer mix and potential growth opportunities, emphasizing the importance of onboarding new customers [33][41]

March 2, 2026 Q4 2025 Earnings Conference Call Forward-looking Statements and Other References Certain statements and information set forth in this presentation contains "forward-looking statements" and "forward-looking information" within the meaning of the Private Securities Litigation Reform Act of 1995. Except for statements of historical fact, certain information contained herein constitutes forward- looking statements which include management's assessment of future plans and operations and are based o ...

Core Insights - Owens Corning reported a net sales increase of 3% year-over-year for 2025, totaling $10.1 billion, despite facing weaker market conditions [6][9] - The company experienced a significant decline in fourth-quarter net sales, down 17% to $2.1 billion compared to the previous year [2][6] - Adjusted EBITDA margin for the full year was 22%, reflecting structural cost improvements and a favorable product mix [9][6] Financial Performance - Fourth-quarter net sales were $2,142 million, down from $2,574 million in Q4 2024, marking a 17% decrease [2] - Full-year net sales reached $10,103 million, an increase of 3% from $9,851 million in 2024 [2] - Adjusted EBITDA for Q4 2025 was $362 million, a 36% decrease from $570 million in Q4 2024, with an EBITDA margin of 17% [2][6] - The diluted EPS from continuing operations was $(2.24) for Q4 2025, compared to $1.45 in Q4 2024 [2][6] Cash Flow and Shareholder Returns - Owens Corning generated $1.8 billion in operating cash flow and returned $1 billion to shareholders through dividends and share repurchases in 2025 [4][6] - The company paid cash dividends of $232 million and repurchased 5.9 million shares for $770 million [7] - The Board of Directors declared a quarterly cash dividend of $0.79 per share, a 15% increase from the previous quarter, marking the 12th consecutive year of dividend growth [7] Strategic Initiatives - The company is focused on improving margins and cash flows, particularly in its Doors business, which faced a non-cash impairment charge of $1.2 billion in 2025 [4][6] - Owens Corning is advancing strategic initiatives, including the sale of its building materials business in China and Korea, and the ongoing sale of its glass reinforcements business [7] - The company is on track to exceed $125 million in enterprise run-rate cost synergies by mid-2026 through operational efficiencies and facility consolidations [7] Market Outlook - The company anticipates continued challenges in residential new construction and remodeling activities at the beginning of 2026, with expectations for market improvement later in the year [15] - For Q1 2026, Owens Corning expects revenue from continuing operations to be approximately $2.1 billion to $2.2 billion, with an adjusted EBITDA margin in the mid-teens [15]

© 2026 BWX Technologies. Inc. All Rights Reserved. The products and services described herein are provided by subsidiaries of BWX Technologies, Inc. Our Purpose: We employ nuclear technology to solve some of the world's most important problems Our Mission: We provide safe and effective nuclear solutions for global security, clean energy, environmental remediation, nuclear medicine, and space exploration Commitment to innovation, operational excellence, a strong safety record, and a focus on ensuring the hig ...

Core Insights - Farmer Mac reported strong financial results for the fiscal year 2025, achieving record net effective spread and outstanding business volumes, marking the tenth consecutive year of record annual core earnings [1][2] - The company announced a 7% increase in its quarterly common stock dividend to $1.60 per share, reflecting its commitment to returning value to shareholders [1][3] - Total core capital reached $1.7 billion with a Tier 1 Capital Ratio of 13.3% as of December 31, 2025, indicating a solid capital position [1][3] Financial Performance - Record core earnings of $182.9 million, or $16.66 per diluted share, representing a 7% year-over-year growth [1][3] - Net income attributable to common stockholders was $182.5 million, or $16.62 per diluted share [1][3] - Net effective spread increased by 13% year-over-year to a record $383.0 million [1][3] - Net interest income grew by 10% year-over-year to $390.7 million [1][3] Business Volume and Liquidity - Farmer Mac provided $10.5 billion in liquidity and lending capacity to lenders serving rural America [1][3] - Outstanding business volume grew by $3.8 billion, reflecting a 13% increase year-over-year [1][3] Dividend Information - The quarterly dividend of $1.60 per share will be payable on March 31, 2026, to shareholders of record as of March 16, 2026 [1][3] - This marks the fifteenth consecutive annual increase in the quarterly common stock dividend [1][3] Balance Sheet Highlights - Total assets as of December 31, 2025, were $35.37 billion, up from $31.32 billion in 2024 [3][4] - Total liabilities increased to $33.65 billion from $29.84 billion in the previous year [3][4] - The company reported total equity of $1.72 billion, an increase from $1.49 billion in 2024 [3][4] Earnings Call Information - A conference call to discuss the fourth quarter and full year 2025 financial results is scheduled for February 19, 2026, at 4:30 p.m. Eastern Time [1][3]

Core Viewpoint - The company is conducting a year-end earnings call and Capital Markets Day update, focusing on growth opportunities and differentiation in its services [1][2]. Group 1: Company Performance - The agenda includes a halftime check-in since the September 2024 Capital Markets Day, indicating a review of progress and performance [2]. - The company aims to highlight its differentiation across the best network, best value, and best customer experiences, which are key competitive advantages [2]. Group 2: Growth Opportunities - Discussion will cover growth opportunities in the core wireless business, broadband business, and new growth areas, emphasizing sustained outperformance for the company [2].

Core Insights - Post Holdings, Inc. reported a net sales increase of 10.1% to $2,174.6 million for the first fiscal quarter ended December 31, 2025, compared to $1,974.7 million in the prior year period [5] - The company raised its fiscal year 2026 Adjusted EBITDA outlook to a range of $1,550-$1,580 million from the previous range of $1,500-$1,540 million [19] Financial Performance - Gross profit was $638.5 million, representing 29.4% of net sales, an increase of 7.3% compared to $595.3 million or 30.1% of net sales in the prior year [5] - Operating profit increased by 11.3% to $238.4 million from $214.1 million in the prior year [6] - Net earnings decreased by 14.6% to $96.8 million compared to $113.3 million in the prior year [7] Segment Performance - Post Consumer Brands segment net sales were $1,103.8 million, up 14.5%, but volumes decreased by 6.1% when excluding the benefit from the 8th Avenue acquisition [10] - Foodservice segment net sales increased by 8.5% to $669.1 million, with segment profit rising by 36.5% to $117.5 million [11] - Refrigerated Retail segment net sales remained flat at $266.6 million, with a segment profit increase of 25.6% to $30.4 million [12] - Weetabix segment net sales grew by 8.1% to $137.9 million, with segment profit increasing by 36.5% to $21.7 million [13] Share Repurchase and Capital Management - During the first quarter, the company repurchased 3.7 million shares for $378.9 million at an average price of $101.57 per share [17] - A new share repurchase authorization of $500 million was approved by the Board of Directors [17] Outlook - The company expects fiscal year 2026 capital expenditures to range between $350-$390 million, including investments in a cage-free egg facility and the completion of a precooked egg facility expansion [19]